Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma
Status:
Withdrawn
Trial end date:
2008-12-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from a person's cancer proteins may help the body build an effective
immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may
increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine
therapy together with GM-CSF may make a stronger immune response and kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving vaccine therapy
together with GM-CSF works in treating patients with CNS lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Simmons Cancer Center University of Texas Southwestern Medical Center